PLSE Quote, Financials, Valuation and Earnings

Nutriband has a net margin of -- compared to Pulse Biosciences's net margin of -211%. Pulse Biosciences's return on equity of -- beat Nutriband's return on equity of -69.58%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -71.08%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 153.91%. Given that Nutriband has higher upside potential than Pulse Biosciences, analysts believe Nutriband is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than Nutriband quarterly revenues of $645.8K. Pulse Biosciences's net income of -$10.1M is lower than Nutriband's net income of -$1.4M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 25.10x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -- compared to Pulse Biosciences's net margin of --. Pulse Biosciences's return on equity of -- beat enVVeno Medical's return on equity of --.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -71.08%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 581.82%. Given that enVVeno Medical has higher upside potential than Pulse Biosciences, analysts believe enVVeno Medical is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.040, suggesting its more volatile than the S&P 500 by 3.991%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than enVVeno Medical quarterly revenues of --. Pulse Biosciences's net income of -$10.1M is lower than enVVeno Medical's net income of -$6.2M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 222.16x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -- compared to Pulse Biosciences's net margin of -882.81%. Pulse Biosciences's return on equity of -- beat SINTX Technologies's return on equity of -148.9%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -71.08%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1585.39%. Given that SINTX Technologies has higher upside potential than Pulse Biosciences, analysts believe SINTX Technologies is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.355%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than SINTX Technologies quarterly revenues of $192K. Pulse Biosciences's net income of -$10.1M is lower than SINTX Technologies's net income of -$1.7M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 1.11x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Beyond Air has a net margin of -- compared to Pulse Biosciences's net margin of -1215.67%. Pulse Biosciences's return on equity of -- beat Beyond Air's return on equity of -225.36%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -71.08%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 873.18%. Given that Beyond Air has higher upside potential than Pulse Biosciences, analysts believe Beyond Air is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison Beyond Air has a beta of 0.154, suggesting its less volatile than the S&P 500 by 84.617%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than Beyond Air quarterly revenues of $1.1M. Pulse Biosciences's net income of -$10.1M is higher than Beyond Air's net income of -$13M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 4.17x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.